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Abstract
Background: Enhanced motility of cancer cells is a critical step in promoting tumor metastasis. Lysophosphatidic acid (LPA),
representing the major mitogenic activity in serum, stimulates migration in various types of cancer cells. However, the
underlying signaling mechanisms for LPA-induced motility of cancer cells remain to be elucidated.
Methodology/Principal Findings: In this study, we found that LPA dose-dependently stimulated migration of MDA-MB-231
breast cancer cells, with 10 mM being the most effective. LPA also increased ERK activity and the MEK inhibitor U0126 could
block LPA-induced ERK activity and cell migration. In addition, LPA induced PAK1 activation while ERK activation and cell
migration were inhibited by ectopic expression of an inactive mutant form of PAK1 in MDA-MB-231 cells. Furthermore, LPA
increased PI3K activity, and the PI3K inhibitor LY294002 inhibited both LPA-induced PAK1/ERK activation and cell migration.
Moreover, in the breast cancer cell, LPA treatment resulted in remarkable production of reactive oxygen species (ROS), while
LPA-induced ROS generation, PI3K/PAK1/ERK activation and cell migration could be inhibited by N-acetyl-L-Cysteine, a
scavenger of ROS.
Conclusions/Significance: Taken together, this study identifies a PI3K/PAK1/ERK signaling pathway for LPA-stimulated
breast cancer cell migration. These data also suggest that ROS generation plays an essential role in the activation of LPA-
stimulated PI3K/PAK1/ERK signaling and breast cancer cell migration. These findings may provide a basis for designing
future therapeutic strategy for blocking breast cancer metastasis.
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Introduction
Lysophosphatidic acid (LPA), a naturally occurring phospho-
lipids, represents the major mitogenic activity in serum. Platelet-
derived LPA is an important mediator in wound healing and tissue
regeneration [1,2]. It is noteworthy that LPA also acts as a
chemoattractant in promoting motility of various types of human
cancer cell. More recently, LPA and its receptor have been
demonstrated to be involved in promoting breast cancer metastasis
to bone [3,4]. Importantly, specific inhibition of LPA receptors
abolishes the migration of cancer cell response to malignant ascites
which contain LPA [5]. However, the molecular mechanisms
underlying the effect of LPA on tumor cell migration are not
completely understood to date.
Previous studies suggest that breast cancer progression is
mediated by Autotaxin (ATX)–LPA signaling axis [6]. ATX and
LPA1–3 receptors are expressed in mammary glands and can
exert multiple effects under physiological conditions [7,8]. LPA is
produced from lysophosphatidylcholine (LPC) by ATX and acts
on the EDG-family LPA receptors, LPA1, LPA2 and LPA3 [9]. As
an important pathway promoting cell survival, the ATX–LPA
signalling axis may initiate tumorigenesis in breast by making cells
susceptible to other genetic mutations, leading to the accumulation
of several aberrant signaling pathways. Indeed, each of these
components of the ATX–LPA signaling axis sufficiently induces
tumorigenesis through the upregulation of many signaling
pathways, including signaling pathways via PI3K, MAPK, Wnt/
b-catenin and estrogen receptor [7,10,11]. In addition, marked
increase in the production of several cytokines by LPA further
advance the disease progression by promoting local inflammation
and angiogenesis [12]. The effects of LPA on cytokine production
and blood vessel formation may contribute to the metastasis of
breast tumors to other organs such as bone. However, the
signaling mechanisms underlying the effect of LPA on breast
cancer cell migration remains unelucidated.
P21-activated kinase 1 (PAK1), a main downstream effector of
Rac1 and Cdc42, plays a pivotal role in signal transduction and
cellular regulation of morphogenesis, survival, proliferation and
motility [13,14,15,16]. Emerging evidence has suggested that
PAK1 is required for the progression and metastasis of cancer cells
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[17,18]. A large body of evidence indicates that PAK1 can be
activated by some stress stimuli such as LPA [19]. In a study of
human melanoma cells, the activation of PI3K-PAK1 signaling
pathway is associated with focal adhesion kinase (FAK) phosphor-
ylation and cell motility induced by LPA [20]. The activation of
PAK1 during LPA stimulation evokes cellular ruffling activity in
three-dimensional collagen matrix cultures [21]. In addition, LPA
has been identified as a potent modulator of extracellular-signal-
regulated kinase (ERK) activity [22]. ERK, a member of the
mitogen-activated protein kinase (MAPK) family, is reported to be
associated with lamellipodial dynamics [23] and chemotactic
migration via a ROS-dependent way [24,25,26]. A recent study
has shown that PAK1 can phosphorylate and activate both MEK1
[27] and Raf [28], which are upstream activators of ERK. Thus, it
is worthwhile to explore whether the PAK1 and ERK signaling
pathway is involved in LPA-induced cancer cell migration. In the
present study, we investigated the signaling mechanisms underly-
ing the effect of LPA on breast cancer cell migration. The PI3K/
PAK1/ERK signaling pathway for LPA-stimulated breast cancer
cell migration is identified and LPA is found to stimulate ROS
generation in breast cancer cells.
Results
LPA stimulates breast cancer cell migration in vitro
To assess the effect of LPA on breast cancer cell migration,
MDA-MB-231 cells were treated with various concentrations of
LPA, and the migration rate of cells was measured by wound
closure assay after the LPA treatment. Similar to the findings of Li
et al [29], our results showed that the migration rate was increased
by 111.9465.60, 159.70622.16, 176.12612.31, 246.27615.60
and 226.87617.61% in the treatment of cells with 0.1, 1, 5, 10,
and 50 mM LPA, respectively, as compared to control (Fig. 1A).
Cell migration was also assessed by transwell migration assay.
MDA-MB-231 cells were treated with 10 mM LPA, the migrated
cell number was increased 30-folds in LPA treated cultures
compared to control (Fig. 1B). To determine whether LPA-
induced cell migration is associated with increased cell prolifer-
ation, MDA-MB-231 cells were treated with 10 mM LPA for 24 h,
and the proliferation of the cells was examined by cell cycle
analysis. The results revealed that the percentages of cells in the S
and G2 phase were not altered significantly in LPA treated cells
compared to the control cells (Fig. 1C). Our MTT assays also
showed that treatment with 10 mM LPA for 24 and 48 h did not
noticeably increase the proliferation of MDA-MB-231 cells
(Fig. 1D).
LPA stimulates cell migration by activating ERK
To explore the mechanism whereby LPA stimulates breast
cancer cell migration, we first examined endogenous ERK
activation after LPA treatment. LPA treatment resulted in a
time-dependent increase in ERK activity, as determined by
Western blotting with an antibody against the phosphorylated
form of ERK (Fig. 2A). ERK activity was increased 5 to 60 min
after 10 mM LPA treatment, with a maximum at 15–30 min. ERK
activity was returned to basal levels at 120 min. As a control, the
levels of total ERK were constant at all these time points (Fig. 2A).
We also treated cells with different doses of LPA (0.1–10 mM) for
15 min, and found that LPA dose-dependently activated ERK in
MDA-MB-231 cells (Figure S1).
Since ERK regulates cell migration not only depending on its
phosphorylation status but also on its redistribution to the nucleus
and plasma membrane [30], we also examined P-ERK localiza-
tion in cultured cells after LPA treatment. Immunofluorescence
staining revealed that P-ERK was weak and localized in the
cytoplasm of serum-starved cells. However, P-ERK abundance
was obviously increased in the cytoplasm, and large amounts of P-
ERK could also be found in the nucleus and periphery of the cells
at 15 min after exposure to LPA; The P-ERK was still detectable
in both nucleus and cytoplasm at 1 h after the addition of LPA
and was diminished in the nucleus and cytoplasm 2 h later
(Fig. 2B).
To determine whether this nucleus translocation of P-ERK was
associated with an increase of ERK transcriptional activity, we
chose to analyze the level of one of these genes, MMP-9, which is
frequently used as a primary mediator of cell migration and
invasion [31]. We first quantified the levels of MMP-9 mRNA
during LPA stimulation with RT-PCR. As shown in Figure S2,
MMP-9 mRNA increased significantly 1 h after LPA stimulation,
then decreased to near baseline levels approximately 2 h later.
Pretreatment with LY294002 or U0126 inhibited LPA-stimulated
MMP-9 induction in MDA-MB-231 cells. However, VEGF
transcript levels in MDA-MB-231 cells were not altered in the
presence of LPA (Figure S2). These results suggest that nucleus
translocation of P-ERK might be required for the transcription of
some mediators of migration such as MMP-9 induction.
To determine whether LPA stimulated migration of breast
cancer cells depended on ERK activation, we investigated the
effect of MEK inhibitor U0126 on cell migration using wound
closure assay. Treatment of cells with 10 mM LPA increased the
migration of MDA-MB-231 cells by 2.5 folds when compared with
control cells. Pretreatment with U0126 not only eliminated LPA-
stimulated migration, but also reduced cell migration in the
absence of LPA treatment (Fig. 2C). These results indicate that the
activation of ERK is essential for both basal and LPA-stimulated
breast cancer cell migration.
PAK1 mediates LPA-induced ERK activation and cell
migration
Previous reports have shown that growth factor-induced ERK
activation is PAK1-dependent, and Thr 423, which resides in the
activation loop of the catalytic domain, is a key intramolecular
phosphorylatable residue for completing enzymatic activation of
PAK1 [32]. Therefore, we examined whether PAK1 activation
also occurred in our system. Western blotting analysis showed that
the amount of phosphorylated PAK1 at Thr 423 was increased
significantly from 5 to 30 min after LPA stimulation with maximal
activation at 15 min. However, after 30 min it declined toward
basal levels (Fig. 3A and B).
To determine whether LPA activates ERK via the PAK1
pathway, we overexpressed an inactive mutant of PAK1 in
MDA-MB-231 cells and showed that it inhibited LPA-induced
ERK phosphorylation. MDA-MB-231 cells transfected with either
an empty vector or a PAK1 K299R expression vector were
stimulated with 10 mM LPA for 15 min and ERK activity was
examined. Following LPA stimulation, the activity of ERK was
increased significantly in the control cells transfected with the
empty vector, but it was abolished in the cells transfected with the
PAK1 K299R expression vector (Fig. 3C).
To further determine whether LPA stimulates cancer cell
migration in a PAK1-dependent manner, we investigated
MDA-MB-231 cells migration using wound closure assay after
transfecting these cells with the inactive mutant of PAK1
expression vector. 18 h after treatment with 10 mM LPA, the cell
migration rate was increased significantly by 234.55627.31%
compared with control cells without LPA treatment. However, in
cells transfected with the PAK1 K299R expression vector, such
PAK1 Signaling in Breast Cancer Cell Migration
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(Fig. 3D). Consequently, the activation of PAK1 is essential for
LPA-stimulated breast cancer cell migration.
LPA induces PAK1/ERK activation and cell migration
through PI3K pathway
Previous report has shown that PI3K can activate both PAK1
and ERK in natural killer cells [33]. To determine whether PI3K
is the upstream mediator of PAK1/ERK activation by LPA in our
system, western blotting analysis of P-Akt (Ser473), a well accepted
downstream target of PI3K, was used to determine the PI3K
activity [34,35]. The Results revealed a time-dependent increase
in PI3K activity following LPA treatment. P-Akt was induced
significantly from 5 to 15 min after LPA stimulation and maximal
activation was at 5 min. P-Akt abundance returned to basal levels
15 min later (Fig. 4A).
To determine whether LPA-stimulated PAK1 and ERK
activities are PI3K-dependent, we blocked PI3K activity by
treating the cells with LY294002, a PI3K inhibitor, and examined
PAK1 and ERK activities after stimulation with LPA. The results
showed that pretreatment with 10 mM LY294002 largely inhibited
LPA-induced PAK1 phosphorylation in comparison with control
cells (Fig. 4B). ERK phosphorylation was also inhibited by
LY294002 (Fig. 4C).
The effect of PI3K inhibitor on cell migration was also
investigated using wound closure assay. Pretreatment with
10 mM LY294002 resulted in a remarkable inhibition of both
basal and LPA-promoted cell migration (Fig. 4D). These results
Figure 1. Effect of LPA on MDA-MB-231 cell migration. (A) Relative cell migration rate was determined using wound closure assay in MDA-MB-
231 cells incubated in the absence (control) or presence of 0.1, 1, 5, 10 or 50 mM LPA for 18 h. (B) The cell migration was assessed by the transwell
migration assay in MDA-MB-231 cells incubated in the absence (control) or presence of 10 mM LPA for 3 h. Representative micrographs of the
migrated cells stained with crystal violet (upper panel) and the migrated cell number per field (lower panel). (C) MDA-MB-231 cells were cultured in
the absence (control) or presence of 10 mM LPA for 24 h and cell cycle was analyzed by flow cytometry. (D) MDA-MB-231 cells were cultured in the
absence (control) or presence of 10 mM LPA for 24 or 48 h and cell proliferation was analyzed by MTT assay. Each value is the mean 6 SD of 6
independent determinations. *: P,0.05, **: P,0.01 in the cultures with LPA relative to the cultures without LPA.
doi:10.1371/journal.pone.0015940.g001
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in mediating LPA-stimulated breast cancer cell migration.
ROS generation is required for LPA-induced PI3K/PAK/
ERK activation and cell migration
ROS generation is frequently associated with an aggressive
phenotype in human cancer [36]. We also examined the effect of
LPA on ROS generation in cultured breast cancer cells.
Superoxide anion and hydrogen peroxide (H2O2) production in
cells were measured by fluorescent staining with dihydroethidium
(DHE) and CM2-DCFHDA, respectively. The staining results
revealed that superoxide anion and H2O2 abundance was weak in
serum-starved cultured cells, but they were increased dramatically
in 10 mM LPA-treated cells (Fig. 5A).
To investigate whether ROS generation leads to LPA-induced
activation of the PI3K/PAK1/ERK signaling pathway and cell
migrationinculturedbreastcancercells,N-acetyl-L-cysteine(NAC),
a known scavenger of ROS, was used and its effect on LPA-induced
PI3K/PAK1/ERK activation was examined. Pretreatment with
2 mM NAC remarkably abolished superoxide anion and hydrogen
peroxide (H2O2) production induced by LPA (Fig. 5A). Pretreat-
ment with 2 mM NAC also largely inhibited LPA-induced PI3K,
PAK1 and ERK activation (Fig. 5C). Furthermore, basal and LPA-
stimulated cell migrations were blocked markedly by the pretreat-
ment with NAC (Fig. 5B). These results indicate that LPA can
stimulate ROS generation in breast cancer cells, and which may be
an important mechanism for the stimulation of PI3K/PAK1/ERK
signaling pathway and cell migration by LPA.
Discussion
LPA and its receptors, LPA1 and LPA2, have been implicated
in breast cancer [37]. In an in vivo model, the activation of LPA1
promotes breast cancer cell metastasis to the bone [4]. Similarly, in
our system, breast cancer cell migration rate was accelerated after
LPA treatment comparing with the control, but cell proliferation
was not altered. Therefore, LPA directly activates the migration of
breast cancer cells, which is a critical step for tumor metastasis.
Based on this, the signaling mechanisms underlying the effect of
LPA on promoting breast cancer cell migration were investigated.
A primary observation in the present study is that LPA induced
activation of ERK in a time-dependent fashion in breast cancer
cells. In addition, we observed that LPA not only enhanced the
phosphorylation level of ERK in the cytoplasm and but also
increased its redistribution from cytoplasm to nucleus and
periphery of the cells. ERK is a known effector for cytoskeletal
regulation and focal adhesion renewal. ERK activation promotes
migration of various types of cell, including endothelial cells
[38,39], mesenchymal stem cells [40] and pancreatic cancer cells
[41]. Previous study has shown that the activation of MAPK
mediates LPA-stimulated preosteoblast migration [22], and is
linked to the progression of breast cancer [42]. Our results found
that when ERK signaling was blocked, LPA-stimulated cell
migration was dramatically diminished. Therefore, our results
suggest that ERK activation serves as a mediator of LPA-
stimulated breast cancer cell migration.
We next examined the potential activators for ERK in our
system. A previous study has demonstrated that the expression of a
constitutively active form of PAK1 induces the rapid formation of
lamellipodia, filopodia, and dorsal ruffles, as well as an increase in
the reorganization of actin cytoskeleton and cell migration [43].
PAK1 has been reported to regulate the ERK pathway by direct
interaction between PAK1 and Raf and MEK. PAK directly
phosphorylates MEK1 on S298, which then induces MEK1
autophosphorylation on S218/222 and increases kinase activity
toward ERK [44] and phosphorylates Raf on Ser338 [28], which
Figure 2. LPA-stimulated cell migration occurred by activation of ERK. (A) Effect of LPA stimulation on phosphorylation of ERK at Thr202/
Tyr204. Confluent, serum-starved cells were treated with 10 mM LPA for the indicated periods. After stimulation, cells were analyzed for P-ERK or total
ERK as described under ‘‘Experimental Procedures.’’ Data are presented as mean6SD of 3 determinations. (B) Representative micrographs of cells
treated with 10 mM LPA for 0 (control), 15, 60 and 120 min and stained immunofluorescence for P-ERK. (C) Effect of U0126 on LPA-stimulated cell
migration. Cells were incubated for 18 h in the absence or presence of 10 mM U0126, with 10 mM LPA or without LPA. Data are presented as
mean6SD of 8 independent determinations. *: P,0.05 in the cultures with LPA relative to the cultures without LPA. #:P,0.05 in the cultures with
LPA and U0126 relative to the cultures with LPA alone.
doi:10.1371/journal.pone.0015940.g002
PAK1 Signaling in Breast Cancer Cell Migration
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15940is known as MEK activator. Our results show that LPA induces a
time-dependent increase in PAK1 activity. Blocking PAK1 activity
by ectopic expression of a kinase-dead PAK1 mutant significantly
prevents LPA-induced ERK activation and cell migration.
Previous study has shown that the inhibition of PAK1 activity
down-regulates ERK signal transduction and reduces cell
migration through affecting actin and adhesion dynamics [45].
Therefore, it may be reasonable to think that LPA-induced
activation of ERK and enhanced cell migration is mediated
through PAK1.
We then examined possible activators of PAK1 in our system.
The activation of PI3K might affect the PAK1 signaling cascade.
For example, the inhibition of PI3K activity blocks the activation
of PAK1 and cell migration in response to heregulin [46].
Meanwhile, the association of PI3K with PAK1 has been reported
to regulate PAK1 kinase activity and lead to cytoskeletal
reorganization [47]. There has a good evidence suggesting a link
from PI3K and Rac1, via PAK1, to ERK activation, which is
essential for the regulation of cytotoxicity in natural killer cells
[33]. Consistent with these reports, our results reveal that LPA
triggers a rapid stimulation of PI3K activity. The selective PI3K
inhibitor LY294002 effectively blocks LPA-induced PAK1 activa-
tion and cell migration. Moreover, our results show that PI3K
inhibitor can also inhibit LPA-induced ERK activation. Conse-
quently, we conclude that PI3K is an upstream component of the
PAK1/ERK signaling pathway in LPA-stimulated breast cancer
cells.
It is not clear whether PI3K mediates ERK activation through
other ways in our system. Akt is a crucial downstream effector of
PI3K and is likely to be responsible for many biological
consequences of PI3K activation. Previous studies demonstrated
that Ras-Raf-MEK-ERK and PI3K-Akt signaling pathways can
crosstalk, and reported that activation of Raf-MEK-ERK pathway
by downregulated Akt in some cell types [48–50]. Cechin SR et al.,
Figure 3. LPA activated ERK and enhanced cell migration mediated through PAK1. (A & B) Effect of LPA stimulation on phosphorylation of
PAK1. Confluent, serum-starved cells were treated with 10 mM LPA for the indicated periods. LPA-stimulated phosphorylation of PAK1 at Thr423 was
determined as described under ‘‘Experimental Procedures.’’ (C) LPA activated ERK dependent on PAK1. MDA-MB-231 cells transfected with either an
empty vector or a PAK1 K299R expression vector were stimulated with 10 mM LPA for 15 min and ERK activity was examined. (D) Effect of the inactive
mutant of PAK1 on LPA-stimulated migration. Cells transfected with empty vector or the PAK1 K299R expression vector were incubated with 10 mM
LPA for 18 h and the cell migration rate was assessed by wound closure assay. Data are presented as mean6SD of 8 determinations. *: P,0.05 in the
cultures with LPA relative to the cultures without LPA. #: P,0.05 in the cells transfected with the PAK1 K299R expression vector with LPA relative to
the cells transfected with empty vector with LPA.
doi:10.1371/journal.pone.0015940.g003
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activity was completely dependent on PI3K, and the PI3K/Akt
pathway was not reduced significantly by inhibition of ERK,
suggesting that the ERK activity could be implicated in the
stimulation of PI3K pathway by LPA [51]. The role of several
other signaling molecules that function downstream of PI3K in
controlling ERK activation and cell migration remains to be
determined. Then another question arises about the relationship
between the activation of PI3K and PAK1 after LPA treatment.
Although activation of PAK1 by PI3K via sequential activation of
Rac and Cdc42 is well characterized [33,52], a number of
GTPase-independent mechanisms may also modify PAK activity
and function. For example, PAK1 can be directly phosphorylated
on Thr423 by PDK1 [53]. In addition, PI3K might also directly
Figure 4. LPA activated PAK1/ERK and enhanced cell migration mediated through PI3K. (A) Effect of LPA stimulation on phosphorylation
of Akt. Confluent, serum-starved cells were treated with 10 mM LPA for the indicated periods. LPA-stimulated phosphorylation of Akt was determined
as described under ‘‘Experimental Procedures.’’ (B) LPA activation of PAK1 was dependent on PI3K. (C) LPA activation of ERK was dependent on PI3K.
After treatment with 10 mM LY294002 for 30 min, cells were stimulated with 10 mM LPA for 15 min and then cells were analyzed by PAK1 (B) or ERK
(C) assay as described under ‘‘Experimental Procedures.’’ Data are presented as mean6SD of 3 independent determinations. (D) Effect of PI3K
inhibitor on LPA-stimulated cell migration. After pretreatment with 10 mM LY294002 for 30 min, cells were incubated with 10 mM LPA for 18 h and
the cell migration rate was determined by wound closure assay. Data are presented as mean6SD of 8 independent determinations. *: P,0.05 in the
cultures with LPA relative to the cultures without LPA. #:P,0.05 in the cultures with LPA and LY294002 relative to the cultures with LPA alone.
doi:10.1371/journal.pone.0015940.g004
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Cdc42/Rac1 or Akt are not activated, PI3K activation can still
induce PAK1 activity in renal proximal tubule cells, and it also
demonstrates that PI3K induces PAK1 activation through binding
to the N-terminal regulatory domain of PAK1 (amino acids 67–
150) [47]. The mechanism whereby PI3K regulates PAK1
activation in this study remains to be elucidated.
Many studies suggest that ROS-induced damage is associated
with aging and various degenerative diseases. Elevated oxidative
status has also been found in some types of cancer cells, which
contributes to carcinogenesis [54]. Although ROS plays a central
role in the key intracellular signal transduction pathway for a
variety of cellular processes, a functional significance of PI3K-
PAK1-ERK signaling by ROS was not described. The earlier
report showed that PDGF-induced migration of vascular smooth
muscle cells (VSMC) is ROS-dependent and Src/PDK1/PAK1
signaling pathway is identified as a ROS-sensitive mediator of cell
migration [55]. In contrast, our results show that LPA treatment
resulted in a significant increase in the production of ROS in
breast cancer cell line MDA-MB-231. Furthermore, decreased
activation of PI3K and reduced phosphorylation of PAK1 and
ERK were observed after inhibition of ROS production, which
correlated with ablation of cell migration, thus suggesting a
dependency of ROS on PI3K-PAK1-ERK signaling pathway in
MDA-MB-231 cells.
It remains unclear how LPA causes the elevation of ROS in
breast cancer cells. Previous studies demonstrate that LPA
enhances Rac1 activation, and Rac1 has been identified as a
necessary component for ROS generation in a variety of cells in
response to growth factors and cytokines [56,57]. It is noteworthy
that Rac1 constitutes part of the structure of NADPH oxidase and,
in this manner, participates in the control of the intracellular ROS
Figure 5. ROS is required for LPA-induced PI3K, PAK1 and ERK activation and cell migration. (A) Representative micrographs of MDA-
MB-231 cells incubated without LPA (control, left panel) or with 10 mM LPA (middle panel) or with both 10 mM LPA and 2 mM NAC (right panel) and
stained with DHE (upper panel) or with CM2-DCFHDA (lower panel). (B) Effect of ROS inhibitor on LPA-stimulated migration. After pretreatment with
2 mM NAC for 1 h, cells were incubated with 10 mM LPA for 18 h, the migration rate was determined by wound closure assay. (C) Effect of NAC on
LPA-induced PI3K, PAK1 and ERK phosphorylation. After treatment with 2 mM NAC for 1 h, cells were stimulated with 10 mM LPA for 15 min and then
cells were analyzed by Akt or PAK1 or ERK assay as described in ‘‘Experimental Procedures’’. (D) Relative P-Akt expression levels. (E) Relative P-PAK1
(Thr423) expression levels. (F) Relative P-ERK expression levels. *: P,0.05 in the cultures with LPA relative to the cultures without LPA. #:P,0.05 in the
cultures with LPA and NAC relative to the cultures with LPA alone.
doi:10.1371/journal.pone.0015940.g005
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stimulates ROS generation in breast cancer cells through the
activation of Rac1.
In summary, we have identified a signaling pathway that is
implicated in LPA-induced breast cancer cell migration. LPA
treatment can lead to the activation of the PI3K/PAK1/ERK
cascade in breast cancer cells and contribute to breast cancer
migration. We have also found that LPA can stimulate ROS
generation in breast cancer cells, which may serve as an important
mediator for LPA to stimulate breast cancer cell migration
through the activation of PI3K/PAK1/ERK signaling pathway.
These findings are of potential pathophysiological importance for
understanding the integration of migration-related signaling and
shed light on new therapeutic targets for breast cancer.
Materials and Methods
Cells and plasmids
Human breast cancer cell line MDA-MB-231 was obtained
from the American Type Culture Collection (ATCC, HTB26).
Cells were maintained in L-15 medium supplemented with 10%
(v/v) fetal bovine serum (FBS), 100 unit penicillin/ml, 100 mg/ml
streptomycin and cultured at 37uC in a humidified atmosphere.
Cells were grown on coverslips for fluorescence staining and on
plastic dishes for protein extraction. Cells were made quiescent by
serum starvation overnight followed by drug treatment.
pCMV6M plasmid containing PAK1 K299R mutant insert was
kindly provided by Dr. Jonathan Chernoff, and has been described
previously [18]. The K299R PAK1 insert was removed from the
pCMV6M vector and inserted into the multiple cloning site of the
pEGFP-N1 vector. MDA-MB-231 cells were transfected with
either the pEGFP-N1 vector or PAK1 K299R expression pEGFP-
N1 vector using lipofectamine 2000. Maximal expression was
achieved at 48 h post transfection and the transfection efficiency
was approximately 40% as detected by green fluorescent protein
(GFP) under microscopic observations.
Reagents and antibodies
Oleoyl-L-a-lysophosphatidic acid sodium salt (LPA), N-acetyl-
L-cysteine (NAC), LY294002 were purchased from Sigma, USA.
U0126 was obtained from Alexis, Switzerland. Trypsin and
Dimethyl Sulfoxide (DMSO) were obtained from Amresco, USA.
L-15 medium was the product of Gibco, USA. FBS was purchased
from Hyclone, USA. Enhanced Chemiluminescence (ECL)
reagent kit was purchased from Pierce, USA. Cell culture inserts
were the product of Falcon, USA. The primary antibodies
including rabbit anti-Akt antibody, rabbit anti-phospho-Akt
(Ser473) antibody, rabbit anti-PAK1 antibody, rabbit anti-PAK1
(Thr423) antibody were purchased from Cell Signaling Technol-
ogy, USA. Mouse anti-ERK antibody and goat anti-phospho-
ERK (Thr202/Tyr204) antibody were obtained from Santa Cruz,
USA. Mouse anti-actin antibody was purchased from Chemicon,
USA. Corresponding HRP-conjugated secondary antibodies
raised in goats were obtained from Santa Cruz, USA. TRIzol
reagent, Lipofectamine 2000, 29,79-Dichlorofluorescein diacetate
(CM2-DCFHDA) and dihydroethidium (DHE) were obtained
from Invitrogen, USA.
Wound closure assay in vitro
MDA-MB-231 cells were plated in a 96-well plate. Approxi-
mately 48 h later, when cells were 95,100% confluent, cells were
incubated overnight in L-15 supplemented with 0.1% (w/v) BSA.
Wounding was performed by scraping through the cell monolayer
with a 10 ml pipette tip. Medium and nonadherent cells were
removed, and cells were washed twice with PBS, and new medium
with or without LPA coupled with various inhibitors was added.
Cells were permitted to migrate into the area of clearing for 18 h.
Wound closure was monitored by visual examination under
microscope.
Transwell migration assay
MDA-MB-231 cells in exponential growth were harvested,
washed, and suspended in L-15 medium without FBS. Cells
(1610
6) were seeded into polycarbonate membrane inserts (8 mm
pore size) in 24-transwell cell culture dishes. Cells were allowed to
attach to the membrane for 30 min before the addition of
inhibitors. The lower chamber was filled with 800 ml of L-15
medium without FBS containing 10 mM LPA as a chemoattrac-
tant. Cells were permitted to migrate for 3 h. After the incubation,
stationary cells were removed from the upper surface of the
membranes. The cells that had migrated to the lower surface were
fixed and stained with 0.1% crystal violet. The number of stained
cells was counted under an ocular microscope.
Cell proliferation assays
MDA-MB-231 cells were cultured in the absence or presence of
LPA for 24 or 48 h and the proliferation of the cells was analyzed
by staining with propidium iodide and flow cytometry analyses or
MTT assay as described previously [58].
Immunofluorescence staining
Cells used for immunostaining were fixed in 3.7% paraformal-
dehyde in PBS for 30 min, permeabilized in 0.1% Triton X-100
and blocked in PBS containing 1% BSA for 1 h at room
temperature. The cells were incubated with anti-phospho-ERK
(Thr202/Tyr204) for 2 h followed by incubation with rhodamine-
conjugated anti-rabbit antibody for 1 h at room temperature
within a moist chamber. After wash with 0.05% Tween 20-PBS,
the samples were mounted with aqueous mounting medium.
Images were collected using an Olympus BX51 microscope
coupled with an Olympus DP70 digital camera.
Intracellular ROS staining
MDA-MB-231 cells were seeded in 6-well plates at the density
of 1610
5 cells per well on a cover-slip overnight. Cells were
stained with CM2-DCFHDA (5 mM) or DHE (10 mM) for 15 min
at 37uC, then washed with PBS thrice, and fixed with 4%
formaldehyde. Images were captured using an Olympus BX51
microscope coupled with an Olympus DP70 digital camera. Green
fluorescence (DCF) intensity was quantitated using the microscope
with 485-nm excitation and 530-nm emission settings, respectively.
Red fluorescence (HE) fluorescence was measured with 480-nm
excitation and 650-nm emission settings.
SDS-PAGE and western blot analysis
Subconfluent cells were lysed with ice-cold RIPA lysis buffer
(50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 1 mM
sodium fluoride, 1 mM EDTA, 1 mM PMSF, and 1% cocktail of
protease inhibitors) pH 7.4. The lysates were then clarified by
centrifugation at 12,000 g for 20 min at 4uC. Protein concentra-
tion in the supernatant was quantitated by the protein assay kit
(Bio-Rad). Equal amount of samples was run on a 10% sodium
dodecyl sulphate polyarcylamide gel electrophoresis (SDS-PAGE).
The samples were then transferred onto polyvinylidene difluoride
(PVDF) membrane with a Bio-Rad transfer unit at 20 V for 1 h at
room temperature. Membranes were blocked in blocking buffer
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60 min followed by incubation with the primary antibodies and
then incubated with the corresponding HRP-conjugated second-
ary antibodies. The immunoblotted proteins were visualized with
ECL reagents. Protein expression was normalized against b-actin.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNAs were isolated with TRIzol reagent. First-strand
cDNAs were synthesized using total RNAs, avian myeloblastosis
virus (AMV) reverse transcriptase, and an oligo (dT) primer.
Primers used for PCR amplification were as follows: GAPDH: 59-
TGAACGGGAAGCTCACTGG-39 (sense) and 59-TCCACCA-
CCCTGTTGCTGTA-39 (antisense) (307 bp); MMP-9: 59-TC-
CCTGGAGACCTGAGAACC-39 (sense) and 59-CGGCAAG-
TCTTCCGAGTAGTT-39 (antisense) (308 bp); VEGF: 59-CG-
GGAACCAGATCTCTCACC-39 (sense) and 59-AAAATGG-
CGAATCCAATTCC-39 (antisense) (233 bp). The PCR for
GAPDH was performed in 26 cycles with the following cycle
profile: 95uC for 30 s, 58uC for 30 s, and 72uC for 30 s. The PCR
for MMP-9 was set up for 28 cycles with the following cycle
profile: 95uC for 30 s, 49uC for 30 s, and 72uC for 40 s. The PCR
for VEGF was set up for 28 cycles with the following cycle profile:
95uC for 30 s, 56uC for 30 s, and 72uC for 30 s. The PCR
products were resolved by electrophoresis on 1% agarose. Images
of electrophoresis were taken using the ChemiDOC XRS Imaging
system (BIO-RAD Laboratories, Hercules, CA, USA).
Statistical analysis
Statistical analyses were carried out using SPSS software.
Student’s t test was used to analyze the differences between two
groups. One-way ANOVA followed by SNK tests were employed
for multiple paired comparisons. Statistical significance was
considered at P,0.05.
Supporting Information
Figure S1 Dose-dependent effects of LPA on ERK
activity. Serum-starved MDA-MB-231 cells were treated with
0.1, 1, 5 or 10 mM LPA for 15 min. After stimulation, cells were
analyzed for P-ERK or total ERK as described under ‘‘Experi-
mental Procedures.’’Total RNA was collected and analyzed for
MMP-9 RNA as described under ‘‘Experimental Procedures.’’ A
representative western blot from one of 3 independent experi-
ments shows similar results.
(TIF)
Figure S2 PI3K and ERK activation is required for LPA-
stimulated MMP-9 induction. Serum-starved MDA-MB-231
cells were treated with 10 mM LPA for the indicated periods. Total
RNA was collected and analyzed for MMP-9 mRNA as described
under ‘‘Experimental Procedures.’’ After treatment with 10 mM
LY294002 or 10 mM U0126 for 30 min, cells were stimulated with
10 mM LPA for 1 h and then cells were analyzed for VEGF and
MMP-9 mRNA levels. A representative RT-PCR from one of 3
independent experiments shows similar results.
(TIF)
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